Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
29.05.2018 14:02:00

Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference

SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the 8th Annual LD Micro Invitational Conference taking place June 4th-6th in Bel Air, CA and at the Jefferies 2018 Global Healthcare Conference taking place June 5th-8th in New York.

Kindred Biosciences, Inc. Logo

Richard Chin, M.D., President and Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the approval of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.

Presentation Details:

8th Annual LD Micro Invitational Conference

Date: Tuesday, June 5, 2018

Time: 7:30 – 8 AM PDT

Location: Luxe Sunset Boulevard Hotel, Track 2

Webcast URL: Click here

Jefferies 2018 Global Healthcare Conference

Date: Friday, June 8, 2018

Time: 2 – 2.25 PM EDT

Location: Grand Hyatt, NY, Ballroom IV

Webcast URL: Click here

An archived version of the above webcasts will be available for 30 days on the Company's website.

About Kindred Biosciences 
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz™ (mirtazapine transdermal ointment) for the management of weight loss in cats.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Russell Radefeld 
KindredBio
russell.radefeld@kindredbio.com 
(650) 701-7904  

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-jefferies-2018-global-healthcare-conference-and-8th-annual-ld-micro-invitational-conference-300655549.html

SOURCE Kindred Biosciences, Inc.

Nachrichten zu Kindred Biosciences Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Kindred Biosciences Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!